- In 2009, statin drug Lipitor achieved sales of $11,434 million
- Licensing and merger/acquisition activities allow pharmaceutical companies to capitalise on high revenue-generating marketed drugs
- Remicade: initially approved for Crohn's disease, now used to treat ankylosing spondylitis, rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis
LONDON--(BUSINESS WIRE)-- Marketed drugs for a range of conditions are subject to in-depth analysis within this new report available on companiesandmarkets.com. Over the next few years an increasing number of pharmaceutical companies will come to mourn the patent expiries of some of their biggest selling marketed products; as revenue streams slide and generic alternatives erode their market share.
Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets
Marketed drug therapies for the treatment of various conditions and disorders, including cardiovascular disease, metabolic disorders, gastrointestinal, musculoskeletal, central nervous system, blood disorders, respiratory and oncology, are investigated within this report.
Some of the world’s highest selling marketed drugs for major indications are due to come off patent in the next few years, impacting upon the revenue streams of many pharmaceutical companies. While patent extensions can revitalise sales for a marketed drug e.g., for new indications or dose levels, they represent a finite amount of protection.
The history behind Bayer’s Ventavis inhalation solution, launched in 2004, is an example of how a company which is not involved in the development of a marketed drug is able to capitalise on its success. Bayer awarded licensing rights to CoTherix Inc, but the company was acquired by Actelion in 2006, which subsequently gained some of the rights, and royalties, of the drug.
Global best-selling statin – Lipitor – saw sales of $11,434 million in 2009, but 2011 will see the expiry of Pfizer’s patent on the gold-standard product. The expiry will see a reduction in Lipitor’s majority share of the antidyslipidemic market.
The 195 page report was published in August 2011 and provides a comparative analysis of marketed drugs in major indications. All marketed drugs are discussed at length within the report, with specific reference to their safety and efficacy profiles, and the revenues they generate.
Report Details:
CONTACT:
Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health
MEDIA:
| Logo |